Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 24710020)

1.

Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men.

Jeong CW, Lee S, Jung JW, Lee BK, Jeong SJ, Hong SK, Byun SS, Lee SE.

PLoS One. 2014 Apr 7;9(4):e94441. doi: 10.1371/journal.pone.0094441. eCollection 2014.

2.

Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?

Lee DH, Jung HB, Park JW, Kim KH, Kim J, Lee SH, Chung BH.

Yonsei Med J. 2013 May 1;54(3):665-71. doi: 10.3349/ymj.2013.54.3.665.

3.

Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH.

Eur Urol. 2012 Mar;61(3):577-83. doi: 10.1016/j.eururo.2011.11.012. Epub 2011 Nov 15.

PMID:
22104592
4.

Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.

Trottier G, Roobol MJ, Lawrentschuk N, Boström PJ, Fernandes KA, Finelli A, Chadwick K, Evans A, van der Kwast TH, Toi A, Zlotta AR, Fleshner NE.

BJU Int. 2011 Oct;108(8 Pt 2):E237-44. doi: 10.1111/j.1464-410X.2011.10207.x. Epub 2011 Apr 20.

PMID:
21507190
5.

Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.

van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Roobol MJ.

Eur J Cancer. 2012 Aug;48(12):1809-15. doi: 10.1016/j.ejca.2012.02.002. Epub 2012 Mar 7.

PMID:
22406050
6.

External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.

Zhu Y, Wang JY, Shen YJ, Dai B, Ma CG, Xiao WJ, Lin GW, Yao XD, Zhang SL, Ye DW.

Asian J Androl. 2012 Sep;14(5):738-44. doi: 10.1038/aja.2012.28. Epub 2012 May 7.

7.

Can the prostate risk calculator based on Western population be applied to Asian population?

Yoon DK, Park JY, Yoon S, Park MS, Moon du G, Lee JG, Schröder FH.

Prostate. 2012 May 15;72(7):721-9. doi: 10.1002/pros.21475. Epub 2011 Aug 11.

PMID:
21837777
8.

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Stephen Jones J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ.

World J Urol. 2012 Apr;30(2):181-7. doi: 10.1007/s00345-011-0818-5. Epub 2011 Dec 31.

9.

Compliance with biopsy recommendations of a prostate cancer risk calculator.

van Vugt HA, Roobol MJ, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Steyerberg EW, Korfage I.

BJU Int. 2012 May;109(10):1480-8. doi: 10.1111/j.1464-410X.2011.10611.x. Epub 2011 Sep 20.

PMID:
21933335
10.

Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction.

Oliveira M, Marques V, Carvalho AP, Santos A.

BJU Int. 2011 Jun;107(11):1780-3. doi: 10.1111/j.1464-410X.2010.09727.x. Epub 2010 Sep 30.

PMID:
20883487
11.

Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population.

Foley RW, Lundon DJ, Murphy K, Murphy TB, Galvin DJ, Watson RW.

Ir J Med Sci. 2015 Apr 7. [Epub ahead of print]

PMID:
25843017
12.

Prostate cancer risk assessment tools in an unscreened population.

Lundon DJ, Kelly BD, Foley R, Loeb S, Fitzpatrick JM, Watson RW, Rogers E, Durkan GC, Walsh K.

World J Urol. 2015 Jun;33(6):827-32. doi: 10.1007/s00345-014-1365-7. Epub 2014 Aug 5.

PMID:
25091862
13.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

PMID:
25168616
14.

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

Roobol MJ, Schröder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Vickers AJ, Lilja H, Steyerberg EW.

World J Urol. 2012 Apr;30(2):149-55. doi: 10.1007/s00345-011-0804-y. Epub 2011 Dec 28.

15.

Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ, Thompson I.

J Urol. 2008 Oct;180(4):1303-8; discussion 1308. doi: 10.1016/j.juro.2008.06.038. Epub 2008 Aug 15. Erratum in: J Urol. 2009 Mar;181(3):1507.

PMID:
18707724
16.

Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.

Hernandez DJ, Han M, Humphreys EB, Mangold LA, Taneja SS, Childs SJ, Bartsch G, Partin AW.

BJU Int. 2009 Mar;103(5):609-14. doi: 10.1111/j.1464-410X.2008.08127.x. Epub 2008 Oct 24.

17.

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.

Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, Troyer DA, Leach RJ, Thompson IM.

Urology. 2006 Dec;68(6):1152-5.

PMID:
17169636
18.

Initial biopsy outcome prediction in Korean patients-comparison of a noble web-based Korean prostate cancer risk calculator versus prostate-specific antigen testing.

Park JY, Yoon S, Park MS, Cho DY, Park HS, Moon du G, Yoon DK.

J Korean Med Sci. 2011 Jan;26(1):85-91. doi: 10.3346/jkms.2011.26.1.85. Epub 2010 Dec 22.

19.

Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.

Nguyen CT, Yu C, Moussa A, Kattan MW, Jones JS.

J Urol. 2010 Feb;183(2):529-33. doi: 10.1016/j.juro.2009.10.007. Epub 2009 Dec 14.

PMID:
20006887
20.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk